Chemren Bio-Engineering Co., Ltd.

Apremilast(CC10004) is a novel small molecule inhibitor of PDE4 with an IC50 value of 74 nM.
IC50 value: 74 nM
Target: PDE 4
Apremilast has profound anti-inflammatory properties in animal models of inflammatory disease, as well as human chronic inflammatory diseases such as psoriasis and psoriatic arthritis. Apremilast blocks the synthesis of several pro-inflammatory cytokines and chemokines, such as tumor necrosis factor alpha, interleukin 23, CXCL9, and CXCL10 in multiple cell types. As this novel PDE4 inhibitor interferes with several key processes of inflammation, Apremilast may emerge as a promising new drug for the treatment of chronic inflammatory diseases such as those of the skin and the joints.

[1]. van de Kerkhof PC. Apremilast: a step forward in the treatment of psoriasis? Lancet. 2012 Jun 28.

[2]. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012 Jun 28.

[3]. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey A, Hu A, Stevens R, de Vlam KL. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012 Jun 21. doi: 10.1002/art.34580.

[4]. Shutty B, West C, Pellerin M, Feldman S. Apremilast as a treatment for psoriasis. Expert Opin Pharmacother. 2012 Aug;13(12):1761-70.

[5]. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012 Jun 15;83(12):1583-90.